Robust home brew fragment sizing assay for detection of MET exon 14 skipping mutation in non–small cell lung cancer patients in resource constrained community hospitals
Journal of Pathology and Translational Medicine. 2021;55(5):324-329 
MET Immunohistochemistry Should Be Avoided in Selecting Non–small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis
Clinical Lung Cancer. 2019;20(3):e418-e420
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
Lung Cancer: Targets and Therapy. 2022;Volume 13:33-45
MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy
Lung Cancer. 2021;154:142-145
Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective
Expert Review of Anticancer Therapy. 2021;21(8):877-886
Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
ESMO Open. 2022;7(2):100449
Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of
MET
exon 14
Thoracic Cancer. 2020;12(4):549-552
Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study
Cancer Genetics. 2021;256-257:62-67
New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer
The Oncologist. 2020;25(10):822-825
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies
Cancer Treatment Reviews. 2021;95:102173